Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM)

A. Boiardi, A. Silvani, D. Croci, E. Perego, C. L. Solero

Research output: Contribution to journalArticlepeer-review


We wondered whether second line chemotherapy in recurrent GBM patients might be useful for debulking the tumor mass and improving patient performance status to prepare the way for second surgical intervention. We have treated 18 recurrent glioma patients with high dose methotrexate (HDMTX) plus 5-fluorouracil (5FU). 5 Patients were responders, 6 had stable disease, and 7 disease progression. 6 patients, 3 PRs and 2 SDs, underwent a second operation after two chemotherapy cycles. Disease progression resumed at 11.5±7 weeks in the non reoperated patients, and at 32.6±9.3 weeks in the reoperated group from initiation of neoadjuvant treatment. Survival time in reoperated patients was 82.6 weeks. Although our experience with this policy is still limited, we believe that reoperation in selected recurrent GBM patients can be worthwhile.

Original languageEnglish
Pages (from-to)583-588
Number of pages6
JournalItalian Journal of Neurological Sciences
Issue number7
Publication statusPublished - Oct 1992


  • Glioblastoma neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM)'. Together they form a unique fingerprint.

Cite this